Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
| Autor: | Leo Seman, Hans-Juergen Woerle, Julio Rosenstock, Thomas Hach, Stefan Hantel, Sabine Pinnetti, Ante Jelaska |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Blood Pressure Type 2 diabetes Placebo Gastroenterology Endocrinology Double-Blind Method Glucosides Internal medicine Internal Medicine Empagliflozin medicine Clinical endpoint Humans Hypoglycemic Agents Benzhydryl Compounds Adverse effect Sodium-Glucose Transporter 2 Inhibitors Glycated Hemoglobin Analysis of Variance business.industry Middle Aged medicine.disease Metformin Treatment Outcome Diabetes Mellitus Type 2 Hematocrit Hyperglycemia Sitagliptin Sodium/Glucose Cotransporter 2 Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 15:1154-1160 |
| ISSN: | 1462-8902 |
| Popis: | Aims To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes. Methods This dose-ranging, double-blind, placebo-controlled trial randomized 495 participants with type 2 diabetes inadequately controlled on metformin [haemoglobin A1c (HbA1c) >7 to ≤10%] to receive 1, 5, 10, 25, or 50 mg empagliflozin once daily (QD), or placebo, or open-label sitagliptin (100 mg QD), added to metformin for 12 weeks. The primary endpoint was change in HbA1c from baseline to week 12 (empagliflozin groups versus placebo). Results Reductions in HbA1c of −0.09 to −0.56% were observed with empagliflozin after 12 weeks, versus an increase of 0.15% with placebo (baseline: 7.8–8.1%). Compared with placebo, empagliflozin doses from 5 to 50 mg resulted in reductions in fasting plasma glucose (−2 to −28 mg/dl vs. 5 mg/dl with placebo; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text